Sébastien Rinaldetti

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Rüdiger Hehlmann, Michael Lauseker, Susanne Saußele et al. · Leukemia · 2017 · 339 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Lida Kalmanti, Michael Lauseker, M. C. Muller et al. · Leukemia · 2015 · 274 citations

Medicine, Pharmacology, Pharmacotherapy +5

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Rüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker et al. · Leukemia · 2020 · 92 citations · Full text

Life Sciences, Hematology, Oncology +16

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML

Alice Fabarius, Lida Kalmanti, Christian Dietz et al. · Annals of Hematology · 2015 · 79 citations

Life Sciences, Genetics, Hematology +8

TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer

Neeraj Agarwal, Sébastien Rinaldetti, Bassem Ben Cheikh et al. · Proceedings of the National Academy of Sciences · 2021 · 60 citations · Full text

Medicine, Molecular Biology, Oncology +17